Arrowgrass Capital Partners LP Trimmed Its Vertex Pharmaceuticals (Call) (VRTX) Position, Arris International Plc Ord (ARRS) Shorts Decreased By 1.6%

May 26, 2017 - By Marie Mckinney

Arrowgrass Capital Partners Lp decreased Vertex Pharmaceuticals Inc (Call) (VRTX) stake by 50% reported in 2016Q4 SEC filing. Arrowgrass Capital Partners Lp sold 48 shares as Vertex Pharmaceuticals Inc (Call) (VRTX)’s stock rose 33.61%. The Arrowgrass Capital Partners Lp holds 48 shares with $354,000 value, down from 96 last quarter. Vertex Pharmaceuticals Inc (Call) now has $30.04B valuation. The stock rose 1.00% or $1.19 reaching $119.79. About 1.07M shares traded. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has risen 45.69% since May 26, 2016 and is uptrending. It has outperformed by 28.99% the S&P500.

Arris International Plc Ord (NASDAQ:ARRS) had a decrease of 1.6% in short interest. ARRS’s SI was 7.83M shares in May as released by FINRA. Its down 1.6% from 7.96 million shares previously. With 1.94 million avg volume, 4 days are for Arris International Plc Ord (NASDAQ:ARRS)’s short sellers to cover ARRS’s short positions. The SI to Arris International Plc Ord’s float is 4.37%. About 584,157 shares traded. ARRIS International plc (NASDAQ:ARRS) has risen 22.70% since May 26, 2016 and is uptrending. It has outperformed by 6.00% the S&P500.

Since November 30, 2016, it had 0 insider purchases, and 27 sales for $25.38 million activity. On Wednesday, December 21 the insider BOGER JOSHUA S sold $482,025. Chodakewitz Jeffrey also sold $162,897 worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares. 271 shares were sold by Silva Paul M, worth $31,067. 3,842 shares were sold by SMITH IAN F, worth $336,790. The insider Arbuckle Stuart A sold $3.38 million. $561,415 worth of stock was sold by ALTSHULER DAVID on Monday, February 13. 3,450 shares were sold by Parini Michael, worth $296,631 on Wednesday, February 1.

Analysts await Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to report earnings on July, 26. They expect $0.05 earnings per share, up 600.00% or $0.06 from last year’s $-0.01 per share. VRTX’s profit will be $12.54 million for 598.95 P/E if the $0.05 EPS becomes a reality. After $0.13 actual earnings per share reported by Vertex Pharmaceuticals Incorporated for the previous quarter, Wall Street now forecasts -61.54% negative EPS growth.

Investors sentiment decreased to 0.88 in 2016 Q4. Its down 0.22, from 1.1 in 2016Q3. It worsened, as 48 investors sold VRTX shares while 165 reduced holdings. 46 funds opened positions while 141 raised stakes. 232.42 million shares or 0.81% less from 234.32 million shares in 2016Q3 were reported. Pennsylvania-based Federated Investors Pa has invested 0.02% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Amalgamated Comml Bank reported 26,697 shares or 0.09% of all its holdings. State Board Of Administration Of Florida Retirement reported 367,755 shares or 0.08% of all its holdings. Macquarie Grp Ltd stated it has 235,647 shares. Tower Rech Capital Lc (Trc) invested in 0.05% or 6,723 shares. Aberdeen Asset Public Limited Co Uk has invested 0.01% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Morgan Stanley reported 0.01% stake. Kelly Lawrence W And Assocs Ca holds 0.34% or 21,085 shares. Clearbridge Ltd Liability Corp invested in 8.65 million shares or 0.7% of the stock. Cwm Ltd Liability owns 111 shares. Benjamin F Edwards And Co reported 114 shares. Trexquant Invest Limited Partnership stated it has 0.04% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). First Interstate State Bank holds 0.02% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 1,300 shares. Brown Advisory Incorporated holds 0% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) or 5,491 shares. Janus Cap Mngmt Ltd Liability Co stated it has 0.03% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Arrowgrass Capital Partners Lp increased Waste Mgmt Inc Del (NYSE:WM) stake by 24,972 shares to 25,320 valued at $1.80 million in 2016Q4. It also upped Spdr Series Trust (Put) (XOP) stake by 8,608 shares and now owns 11,138 shares. Bank Amer Corp (NYSE:BAC) was raised too.

Among 17 analysts covering Vertex Pharmaceuticals (NASDAQ:VRTX), 10 have Buy rating, 0 Sell and 7 Hold. Therefore 59% are positive. Vertex Pharmaceuticals had 36 analyst reports since July 31, 2015 according to SRatingsIntel. Raymond James initiated Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on Tuesday, September 13 with “Mkt Perform” rating. The firm has “Outperform” rating given on Tuesday, March 8 by Leerink Swann. The stock of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) earned “Overweight” rating by Morgan Stanley on Friday, October 2. Argus Research maintained the stock with “Buy” rating in Thursday, February 4 report. On Wednesday, March 1 the stock rating was initiated by Citigroup with “Buy”. The stock of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has “Neutral” rating given on Monday, October 24 by H.C. Wainwright. The company was upgraded on Monday, September 28 by Argus Research. Barclays Capital downgraded the shares of VRTX in report on Tuesday, November 29 to “Equal-Weight” rating. The company was maintained on Thursday, April 28 by RBC Capital Markets. On Thursday, February 11 the stock rating was initiated by Oppenheimer with “Perform”.

Among 11 analysts covering Arris Group Inc. (NASDAQ:ARRS), 9 have Buy rating, 1 Sell and 1 Hold. Therefore 82% are positive. Arris Group Inc. had 22 analyst reports since July 24, 2015 according to SRatingsIntel. Goldman Sachs downgraded the shares of ARRS in report on Monday, March 14 to “Neutral” rating. Drexel Hamilton initiated ARRIS International plc (NASDAQ:ARRS) on Friday, July 24 with “Buy” rating. On Monday, September 21 the stock rating was downgraded by Zacks to “Sell”. The stock has “Outperform” rating by RBC Capital Markets on Thursday, July 30. The rating was maintained by Needham on Thursday, February 18 with “Buy”. The rating was maintained by Needham with “Buy” on Thursday, July 30. The firm earned “Market Perform” rating on Tuesday, February 21 by Northland Capital. The company was maintained on Thursday, February 18 by Barclays Capital. The stock of ARRIS International plc (NASDAQ:ARRS) earned “Buy” rating by Needham on Thursday, October 29. The stock has “Overweight” rating by Morgan Stanley on Tuesday, September 20.

ARRIS International plc is a media entertainment and data communications solutions provider. The company has market cap of $5.30 billion. The Firm operates in two divisions: Customer Premises Equipment , and Network & Cloud (N&C). It has a 29.74 P/E ratio. The Firm enables service providers, including cable, telephone, and digital broadcast satellite operators, and media programmers to deliver media, voice and Internet Protocol (IP) data services to their subscribers.

Investors sentiment increased to 1.5 in Q4 2016. Its up 1.17, from 0.33 in 2016Q3. It improved, as 1 investors sold ARRIS International plc shares while 1 reduced holdings. 2 funds opened positions while 1 raised stakes. 557,538 shares or 14.36% more from 487,535 shares in 2016Q3 were reported. Vantage Investment Advsrs Ltd Liability Corp has invested 0.03% in ARRIS International plc (NASDAQ:ARRS). Gemmer Asset Ltd Llc stated it has 0% in ARRIS International plc (NASDAQ:ARRS). Toth Fin Advisory Corporation stated it has 0.09% of its portfolio in ARRIS International plc (NASDAQ:ARRS). Baxter Bros reported 169,830 shares. First Retail Bank Of Omaha holds 0.11% of its portfolio in ARRIS International plc (NASDAQ:ARRS) for 64,640 shares. Schwartz Investment Counsel, a Michigan-based fund reported 310,000 shares.